APVO

Aptevo Therapeutics Inc. (APVO) | Rumor.io

Aptevo Therapeutics

APVO

Attention (50-day avg)0.03%

Attention rank (50-day avg)#235

Bullish sentiment (50-day avg)12%

Price to earnings ratio0

Market capitalization3.5M

Earnings per share456.6

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-26M

Social

What share of all stock conversation is about APVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0.05% +0.05	0% 0

Sep 3

Aptevo Therapeutics Inc. ($APVO) reported a 93% clinical benefit rate with its mipletamig triplet in frontline TP53-mutated acute myeloid leukemia (AML) patients.
The company filed a 424B4 form, which indicates a priced-at-public-exchange (PIPE) transaction priced at $4.03 on August 12, with the stock currently trading at $2.15.
The reported clinical benefit rate of 93% is a significant positive development for Aptevo, with some investors expecting a potential move up in the stock price despite the current downtrend.

Generated by AI

Sentiment

Of the messages about APVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	10.34% -2.7	52.4% -24.84
Bearish	—	—	89.66% +2.7	47.6% +24.84

Bullish· Mar 31

$APVO has a low float of 900k, making it susceptible to short squeezes, with a target price of $10+.
The company has a recent positive conference update and cash on hand, setting it up for a potential price increase.
$APVO is primed for a squeeze, with increasing volume and a strong potential for a 100%+ price move.

Bearish· Jul 8

The price of $APVO may return to its starting point as short sellers take advantage of the current pop.
The company's after-hours and pre-market activity may be manipulated by brokers, leading to unfair market conditions.
The stock's recent pump and dump may be a sign that the market is due for a correction, with the price potentially dropping to $3.50.

Generated by AI

Topics

Of the messages about APVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	83.1%	0.19%	1.97%
Analysts	—	8.45%	49.9%	48.85%
Technical Analysis	—	0%	0.01%	0.36%
Macro	—	8.45%	49.9%	48.77%
Controversies	—	0%	0%	0.04%
Earnings	—	0%	0%	0.01%

Announcements· Jan 9

Aptevo Therapeutics Inc. (APVO) has secured a $60 million equity line of credit with Yorkville Advisors Global, LP, providing flexible access to capital through 2029.
The equity line of credit will be used to fund ongoing clinical development, advance preclinical programs, and support general corporate purposes, with Aptevo having the right to sell shares to Yorkville periodically.
The agreement is expected to support the achievement of key clinical and preclinical milestones, and provide Aptevo with greater flexibility and control over the timing and use of capital.

Technical Analysis· Sep 18

The chart for $APVO shows a perfect ascending triangle, with a potential breakout at $2.80.
The stock appears poised for a breakout if it clears $2.06 with volume, with potential pullback levels at $1.78 or $1.49.
A double bottom and a falling wedge are forming on the 4-hour and daily charts, with potential targets around $5.40 and $20.

Generated by AI

Community

Of the messages about APVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	1.52%	0.26%	14.52%
Newcomers	—	98.48%	99.74%	85.48%

Regulars· Sep 3

Aptevo Therapeutics' mipletamig treatment shows a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML patients, raising hopes for the company's future.
The market's negative reaction to the news, with the stock price declining by 21%, may be an overreaction, as the treatment's efficacy is a significant positive development.
The treatment's 93% clinical benefit rate is a major milestone, and some market participants believe it could lead to a significant increase in the company's value, with some even suggesting a potential sale of the company based on its total addressable market.

Newcomers· Sep 3

Aptevo Therapeutics Inc. ($APVO) reported a 93% clinical benefit rate for its mipletamig triplet in frontline TP53-mutated acute myeloid leukemia (AML) patients, with 11 patients achieving complete remission or CRi.
The clinical benefit rate is significant, especially in a difficult-to-treat subtype of AML, and the company's stock price has been impacted, with a 47% decline in the last three weeks.
Newcomers to discussing $APVO are focusing on the company's recent strong data and the potential for a move up in the stock price, with some expressing skepticism and caution, while others are optimistic about the company's prospects.

Generated by AI

News

Aptevo advances trispecific cancer therapy manufacturing

5d agoInvesting.com

Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

26d agobenzinga.com

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

26d agofinance.yahoo.com

Why is Aptevo Therapeutics stock slumping today?

26d agoInvesting.com

Aptevo reports 93% clinical benefit rate in AML trial subset

26d agoInvesting.com

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

27d agoYahoo Finance

Also Discussed

Investors talking about APVO also mention

#	Name	Attention
1	CaliberCos Inc. Class A Common StockCWD	0%0
2	NRx Pharmaceuticals, Inc.NRXP	0%-0.01
3	Longeveron Inc. Class A Common StockLGVN	0%0
4	PTPI - Petros Pharmaceuticals, Inc.	——
5	Pasithea Therapeutics Corp.KTTA	0%0
6	iSpecimen Inc.ISPC	0%0
7	Cimg Inc.NUZE	0%0
8	Gulf Resources, Inc.GURE	0%new
9	GCL Global Holdings LtdGCL	0%0
10	ADVM - Adverum Biotechnologies, Inc.	——

Aptevo Therapeutics Inc.

Healthcare
Biotechnology

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer. The company uses its proprietary ADAPTIR and ADAPTIR-FLEX platforms to design mono-, bi-, and multi-specific antibody-based therapeutics intended to engage the immune system against tumor cells. Its current pipeline includes candidates for hematologic malignancies and solid tumors, with programs spanning clinical and preclinical development. Aptevo Therapeutics Inc. operates in the oncology and immuno-oncology segments of the healthcare market, where it contributes to the development of targeted biologic therapies for complex cancers. Headquartered in Seattle, Washington, the company concentrates on research-driven product development and collaboration-based innovation in modern cancer treatment.

Website

Location

2401 4th Avenue

Seattle, WA, 98121

United States

Social

What share of all stock conversation is about APVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0.05% +0.05	0% 0

Sep 3

Aptevo Therapeutics Inc. ($APVO) reported a 93% clinical benefit rate with its mipletamig triplet in frontline TP53-mutated acute myeloid leukemia (AML) patients.
The company filed a 424B4 form, which indicates a priced-at-public-exchange (PIPE) transaction priced at $4.03 on August 12, with the stock currently trading at $2.15.
The reported clinical benefit rate of 93% is a significant positive development for Aptevo, with some investors expecting a potential move up in the stock price despite the current downtrend.

Generated by AI

Sentiment

Of the messages about APVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	10.34% -2.7	52.4% -24.84
Bearish	—	—	89.66% +2.7	47.6% +24.84

Bullish· Mar 31

$APVO has a low float of 900k, making it susceptible to short squeezes, with a target price of $10+.
The company has a recent positive conference update and cash on hand, setting it up for a potential price increase.
$APVO is primed for a squeeze, with increasing volume and a strong potential for a 100%+ price move.

Bearish· Jul 8

The price of $APVO may return to its starting point as short sellers take advantage of the current pop.
The company's after-hours and pre-market activity may be manipulated by brokers, leading to unfair market conditions.
The stock's recent pump and dump may be a sign that the market is due for a correction, with the price potentially dropping to $3.50.

Generated by AI

Topics

Of the messages about APVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	83.1%	0.19%	1.97%
Analysts	—	8.45%	49.9%	48.85%
Technical Analysis	—	0%	0.01%	0.36%
Macro	—	8.45%	49.9%	48.77%
Controversies	—	0%	0%	0.04%
Earnings	—	0%	0%	0.01%

Announcements· Jan 9

Aptevo Therapeutics Inc. (APVO) has secured a $60 million equity line of credit with Yorkville Advisors Global, LP, providing flexible access to capital through 2029.
The equity line of credit will be used to fund ongoing clinical development, advance preclinical programs, and support general corporate purposes, with Aptevo having the right to sell shares to Yorkville periodically.
The agreement is expected to support the achievement of key clinical and preclinical milestones, and provide Aptevo with greater flexibility and control over the timing and use of capital.

Technical Analysis· Sep 18

The chart for $APVO shows a perfect ascending triangle, with a potential breakout at $2.80.
The stock appears poised for a breakout if it clears $2.06 with volume, with potential pullback levels at $1.78 or $1.49.
A double bottom and a falling wedge are forming on the 4-hour and daily charts, with potential targets around $5.40 and $20.

Generated by AI

Community

Of the messages about APVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	1.52%	0.26%	14.52%
Newcomers	—	98.48%	99.74%	85.48%

Regulars· Sep 3

Aptevo Therapeutics' mipletamig treatment shows a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML patients, raising hopes for the company's future.
The market's negative reaction to the news, with the stock price declining by 21%, may be an overreaction, as the treatment's efficacy is a significant positive development.
The treatment's 93% clinical benefit rate is a major milestone, and some market participants believe it could lead to a significant increase in the company's value, with some even suggesting a potential sale of the company based on its total addressable market.

Newcomers· Sep 3

Aptevo Therapeutics Inc. ($APVO) reported a 93% clinical benefit rate for its mipletamig triplet in frontline TP53-mutated acute myeloid leukemia (AML) patients, with 11 patients achieving complete remission or CRi.
The clinical benefit rate is significant, especially in a difficult-to-treat subtype of AML, and the company's stock price has been impacted, with a 47% decline in the last three weeks.
Newcomers to discussing $APVO are focusing on the company's recent strong data and the potential for a move up in the stock price, with some expressing skepticism and caution, while others are optimistic about the company's prospects.

Generated by AI

Aptevo Therapeutics

Social

Sep 3

Bullish· Mar 31

Bearish· Jul 8

Announcements· Jan 9

Technical Analysis· Sep 18

Regulars· Sep 3

Newcomers· Sep 3

Aptevo advances trispecific cancer therapy manufacturing

Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

Why is Aptevo Therapeutics stock slumping today?

Aptevo reports 93% clinical benefit rate in AML trial subset

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Also Discussed

Aptevo Therapeutics Inc.

Company Information

Location

Aptevo advances trispecific cancer therapy manufacturing

Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

Why is Aptevo Therapeutics stock slumping today?

Aptevo reports 93% clinical benefit rate in AML trial subset

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Also Discussed

Social

Sep 3

Bullish· Mar 31

Bearish· Jul 8

Announcements· Jan 9

Technical Analysis· Sep 18

Regulars· Sep 3

Newcomers· Sep 3